Statins and cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 5, 2014, Pages 706-712

  Vallianou, Natalia G ^a   Kostantinou, Alexandra ^a   Kougias, Marios ^a   Kazazis, Christos ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NONE

Author keywords

Cancer; Chemotherapy; Mechanisms; Mortality; Statin

Indexed keywords

ACETYLSALICYLIC ACID; CERIVASTATIN; CISPLATIN; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEFITINIB; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PRAVASTATIN; PROTEIN KINASE B; RAS PROTEIN; RHO FACTOR; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTATION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CELL DEATH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; IMMUNOMODULATION; META ANALYSIS (TOPIC); NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; TREATMENT OUTCOME; CHEMISTRY; MORTALITY; NEOPLASMS;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS;

EID: 84904472802     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520613666131129105035     Document Type: Article

References (89)

1. Pignone, M.; Phillips, C.; Mulrow, C. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomised trials. BMJ, 2000, 321, 983-986.
2. Mihos, C.G.; Santana, O. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int. J. Gen. Med., 2011, 4, 261-271.
3. Mihos, C.G.; Salas M.J.; Santana, O. The pleiotropic effects of the hydroxymethyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol. Rev., 2010, 18, 298-304.
4. Zeichner, S.; Mihos, C.G.; Santana, O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: A comprehensive review. J. Cancer. Res., 2012, 8, 176-183.
5. Chan, K.K.; Oza, A.M.; Siu, L.L. The statins as anticancer agents. Clin. Cancer. Res., 2003, 9(1), 10-19.
6. Bonetti, P.O.; Lerman, L.O.; Napoli, C.; Lerman, A. Statin effects beyond lipid lowering-are they clinically relevant? Eur. Heart. J., 2003, 24, 225-248.
7. Sleijfer, S.; van der Gaast, A.; Planting, A.S.T.; Stoter, G.; Verweij, J. The potential of statins as part of anti-cancer treatment. Eur. J. Cancer., 2005, 41, 516-522.
8. Demierre, M.F.; Higgins, P.D.; Gruber, S.B.; Hawk, E.; Lippman, S.M. Statins and cancer prevention. Nat. Rev. Cancer., 2005, 5, 930-942.
9. Singh, P.P.; Singh, S. Statins are associated with reduced risk of gastric cancer: A systematic review and meta-analysis. Ann. Oncol., 2013, Apr 18 [Epub ahead of print].
10. Singh, S.; Singh, A.G.; Singh, P.P.; Murad, M.H.; Iyer, P.G. Statins are associated with reduced risk of esophageal cancer, particularly in patients with barrett's esophagus: A systematic review and metaanalysis. Clin. Gastroenterol. Hepatol., 2013, 11(6), 620-629.
11. Bonovas, S.; Filioussi, K.; Flordellis, C.S.; Sitaras, N.M. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J. Clin. Oncol., 2007, 25, 3462-3468.
12. Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature, 1990, 343(6257), 425-430.
13. Casey, P.J. Protein lipidation in cell signaling. Science., (New York, NY 1995, 268(5208), 221-225.
14. Rando, R.R. Chemical biology of isoprenylation/methylation. Biochem. Soc. Trans., 1996, 24(3), 682-687.
15. Chan, K.K.; Oza, A.M.; Siu, L.L. The statins as anticancer agents. Clin. Cancer. Res., 2003, 9, 10-19.
16. Bansal, D.; Undela, K.; D'Cruz, S.; Schifano, F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS. One, 2012, 7, e46691.
17. Zhu, Y.; Casey, P.J.; Kumar, A.P.; Pervaiz, S. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death. and Disease, 2013, 4, e568.
18. Bishop, A.L.; Hall, A. Rho GTPases and their effector proteins. Biochem. J., 2000, 348(Pt 2), 241-255.
19. Benhar, M.; Dalyot, I.; Engelberg, D.; Levitzki, A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun Nterminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell. Biol., 2001, 21, 6913-6926.
20. Maundrell, K.; Antonsson, B.; Magnenat, E.; Camps, M.; Muda, M.; Chabert, C, Gillieron, C.; Boschert, U.; Vial-Knecht, E.; Martinou, J.C.; Arkinstall, S. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J. Biol. Chem., 1997, 272, 25238-25242.
21. Llevadot, J.; Murasawa, S.; Kureishi, Y.; Uchida, S.; Masuda, H.; Kawamoto, A.; Walsh, K.; Isner, J.M.; Asahara, T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest., 2001, 108, 399-405.
22. Bussolati, B.; Deregibus, M.C.; Fonsato, V.; Doublier, S.; Spatola, T.; Procida, S.; Di Carlo, F.; Camussi, G. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J. Am. Soc. Nephrol., 2005, 16, 1936-1947.
23. Rikitake, Y.; Liao J.K. Rho GTPases, Statins and Nitric oxide. Circ. Res., 2005, 97, 1232-1235.
24. Bouterfa, H.L.; Sattelmeyer, V.; Czub, S.; Vordermark, D.; Roosen, K.; Tonn, J.C. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer. Res., 2000, 20, 2761-2771.
25. DeClue, J.E.; Vass, W.C.; Papageorge, A.G.; Lowy, D.R.; Willumsen, B.M. Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res., 1991, 51, 712-717.
26. Bifulco, M. Therapeutic potential of statins in thyroid proliferative disease. Nat. Clin. Pract. Endocrinol. Metab., 2008, 4, 242-243.
27. Wang, C.Y.; Zhong, W.B.; Chang, T.C.; Lai, S.M.; Tsai, Y.F. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab., 2003, 88, 3021-3026.
28. Wang, E.; Casciano, C.N.; Clement, R.P.; Johnson, W.W. HMGCoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res., 2001, 18, 800-806.
29. Wang, H.R.; Li, J.J.; Huang, C.X.; Jiang, H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin. Chim. Acta., 2005, 353, 53-60.
30. Laezza, C.; Di Marzo, V.; Bifulco, M. v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. Proc. Natl. Acad. Sci., 1998, USA, 95, 13646-13651.
31. Laezza, C.; Fiorentino, L.; Pisanti, S.; Gazzerro, P.; Caraglia, M.; Portella, G.; Vitale, M.; Bifulco, M. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. J. Mol. Med., 2008, 86, 1341-1351.
32. Bifulco, M. Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci., 2005, 77, 1740-1749.
33. Hirai, A.; Nakamura, S.; Noguchi, Y.; Yasuda, T.; Kitagawa, M.; Tatsuno, I.; Oeda, T.; Tahara, K.; Terano, T.; Narumiya, S.; Kohn, L.D.; Saito, Y. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem., 1997, 272, 13-16.
34. Rao, S.; Lowe, M.; Herliczek, T.W.; Keyomarsi, K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene., 1998, 17, 2393-2402.
35. Denoyelle, C.; Albanese, P.; Uzan, G.; Hong, L.; Vannier, J.P.; Soria, J.; Soria, C. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal., 2003, 15, 327-338.
36. Nubel, T.; Dippold, W.; Kleinert, H.; Kaina, B.; Fritz, G. Lovastatin inhibits Rho-regulated expression of E-selectin by TNF-alpha and attenuates tumor cell adhesion. FASEB J., 2004, 18, 140-142.
37. Kusama, T.; Mukai, M.; Iwasaki, T.; Tatsuta, M.; Matsumoto, Y.; Akedo, H.; Nakamura, H. Inhibition of epidermal growth factorinduced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutarylcoenzyme a reductase inhibitors. Cancer Res., 2001, 61, 4885-4891.
38. Wang, I.K.; Lin-Shiau, S.Y.; Lin, J.K. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology, 2000, 59, 245-254.
39. Hindler, K.; Cleeland, C.S.; Rivera, E.; Collard, C.D. The role of statins in cancer therapy. Oncologist., 2006, 11, 306-315.
40. Dimitroulakos, J.; Nohynek, D.; Backway, K.L.; Hedley, D.W.; Yeger, H.; Freedman, M.H.; Minden, M.D.; Penn, L.Z. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood, 1999, 93, 1308-1318.
41. Dimitroulakos, J.; Thai, S.; Wasfy, G.H.; Hedley, D.W.; Minden, M.D.; Penn, L.Z. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk. Lymphoma., 2000, 40, 167-178.
42. Dimitroulakos, J.; Yeger, H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat. Med., 1996, 2, 326-333.
43. Marcelli, M., Cunningham, G.R.; Haidacher, S.J.; Padayatty S.; Sturgis, L.; Kagan, C.; Denner, L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res., 1998, 58, 76-83.
44. Wang, I.K.; Lin-Shiau, S.Y.; Lin, J.K. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol. Toxicol., 2000, 86, 83-91.
45. Cafforio, P.; Dammacco, F.; Gernone, A.; Silvestris, F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis, 2005, 26, 883-891.
46. Frick, M.; Dulak, J.; Cisowski, J.; Jozkowicz, A.; Zwick, R.; Alber, H.; Dichtl, W.; Schwarzacher, S.P.; Pachinger, O.; Weidinger, F. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis, 2003, 170, 229-236.
47. Brouet, A.; Sonveaux, P.; Dessy, C.; Moniotte, S.; Balligand, J.L.; Feron, O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ. Res., 2001, 89, 866-873.
48. Martin-Ventura, J.L.; Blanco-Colio, L.M.; Gomez-Hernandez, A.; Munoz-Garcia, B.; Vega, M.; Serrano, J.; Ortega, L.; Hernandez, G.; Tunon, J.; Egido, J. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke, 2005, 36, 1796-1800.
49. Li, J.; Li, J.J.; He, J.G.; Nan, J.L.; Guo, Y.L.; Xiong, C.M. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway. Cardiovasc. Ther., 2010, 28, 8-14.
50. Garwood, E.R.; Kumar, A.S.; Baehner, F.L.; Moore, D.H.; Au, A.; Hylton, N.; Flowers, C.I.; Garber, J.; Lesnikoski, B.A.; Hwang, E.S.; Olopade, O.; Port, E.R.; Campbell, M.; Esserman, L.J. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat., 2010, 119, 137-44.
51. Martirosyan, A.; Clendening, J.W.; Goard, C.A.; Penn, L.Z. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer, 2010, 10, 103.
52. Hachem, C.; Morgan, R.; Johnson, M.; Kuebeler, M.; El-Serag, H. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am. J. Gastroenterol., 2009, 104, 1241-1248.
53. Poynter, J.N.; Gruber, S.B.; Higgins, P.D.; Almog, R.; Bonner, J.D.; Rennert, H.S.; Low, M.; Greenson, J.K.; Rennert, G. Statins and the risk of colorectal cancer. N. Engl. J. Med., 2005, 352, 2184-2192.
54. Khurana, V.; Bejjanki, H.R.; Caldito, G.; Owens, M.W. Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest., 2007, 131, 1282-1288.
55. Bonovas, S.; Nikolopoulos, G.; Filioussi, K.; Peponi, E.; Bagos, P.; Sitaras, N.M. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur. J. Epidemiol., 2010, 25, 29-35.
56. Bonovas, S.; Filioussi, K.; Sitaras, N.M. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am. J. Gastroenterol., 2008, 103, 2646-2651.
57. Poynter, J.; Gruber, S.; Higgins, P.; Almog, R.; Bonner, J.; Rennert, H.; Low, M.; Greenson, J.; Rennert, G: Statins and the risk of colorectal cancer. N. Engl. J. Med., 2005, 352, 2184-2192.
58. Bonovas, S.; Tsantes, A.; Drosos, T.; Sitaras, N.M. Cancer chemoprevention: A summary of the current evidence. Anticancer Res., 2008, 28, 1857-1866.
59. Bonovas, S.; Filioussi, K.; Sitaras, N.M. Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int. J. Cancer, 2008, 123, 899-904.
60. Undela, K.; Srikanth, V.; Bansal, D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res. Treat., 2012, 135, 261-269.
61. Lochhead, P.; Chan, A.T. Statins and colorectal cancer. Clin. Gastroenterol. Hepatol., 2013, 11, 109-118.
62. Bonovas, S.; Filioussi, K.; Tsantes, A.; Sitaras, N.M. Use of statins and risk of haematological malignancies: A meta-analysis of six randomized clinical trials and eight observational studies. Br. J. Clin. Pharmacol., 2007, 64, 255-262.
63. Bonovas, S.; Filioussi, K.; Tsavaris, N.; Sitaras, N.M. Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol., 2005, 23, 8606-8612.
64. Weverling-Rijnsburger, A.W.; Blauw, G.J.; Lagaay, A.M.; Knook, D.L.; Meinders, A.E.; Westendorp, R.G. Total cholesterol and risk of mortality in the oldest old. Lancet., 1997, 350, 1119-123.
65. Stemmermann, G.N.; Chyou, P.H.; Kagan, A.; Nomura, A.M.; Yano, K. Serum cholesterol and mortality among Japanese American men: The Honolulu (Hawaii) Heart Program. Arch. Intern. Med., 1991, 151, 969-972.
66. Schuit, A.J.; Van Dijk, C.E.; Dekker, J.M.; Schouten, E.G.; Kok, F.J. Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Am. J. Epidemiol., 1993, 137, 966-976.
67. Schatzkin, A.; Hoover, R.N.; Taylor, P.R.; Ziegler, R.G.; Carter, C.L.; Albanes, D.; Larson, D.B.; Licitra, L.M. Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-Up Study. Cancer. Res., 1988, 48, 452-458.
68. Singh, S.; Singh, P.P.; Singh, A.G.; Murad, M.H.; Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis. Gastroenterology., 2013, 144, 323-332.
69. Undela, K.; Srikanth, V.; Bansal, D. Statin use and risk of breast cancer: A meta-analysis of observational studies. Breast Cancer. Res. Treat., 2012, 135, 261-269.
70. Bonovas, S.; Sitaras, N.M. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ., 2007, 176, 649-654.
71. Thompson, S.G.; Higgins, J.P. How should meta-regression analyses be undertaken and interpreted? Stat. Med., 2002, 21, 1559-1573.
72. Bonovas, S.; Filioussi, K.; Tsavaris, N.; Sitaras, N.M. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J. Clin. Oncol., 2006, 24, 4808-4817.
73. Ford, I.; Murray, H.; Packard, C.J.; Shepherd, J.; Macfarlane, P.W.; Cobbe, S.M. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med., 2007, 357, 1477-1486.
74. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet, 2002, 359, 1379-1387.
75. Strandberg, T.E.; Pyorala, K.; Cook, T.J.; Wilhelmsen, L.; Faergeman, O.; Thorgeirsson, G.; Pedersen, T.R.; Kjekshus, J. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet., 2004, 364, 771-777.
76. Heart Protection Study Collaborative Group. Effects on 11 year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 6 years in 20536 high-risk individuals. Lancet, 2011, 6736 (11), 61125-61132.
77. Nielsen, S.F.; Nordestgaard, B.G.; Bojesen, S.E. Statin use and reduced cancer-related mortality. N. Engl. J. Med., 2012, 367, 1792-1802.
78. Zhao, T.T.; Le Francois, B.G.; Goss, G.; Ding, K.; Bradbury, P.A.; Dimitroulakos, J. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: Potential regulation by targeting rho proteins. Oncogene. 2010, 29, 4682-4692.
79. Mantha, A.J.; Hanson, J.E.; Goss, G.; Lagarde, A.E.; Lorimer, I.A.; Dimitroulakos, J. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin. Cancer. Res., 2005, 11, 2398-2407.
80. Ma, L.; Niknejad, N.; Gorn-Hondermann, I.; Dayekh, K.; Dimitroulakos, J. Lovastatin induces multiple stress pathways including lkb1/ampk activation that regulate its cytotoxic effects in squamous cell carcinoma cells. PLoS ONE, 2012, 7(9), e46055.
81. Taylor-Harding, B.; Orsulic, S.; Karlan, B.Y.; Li, A.J. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol. Oncol., 2010, 119(3), 549-556.
82. Bardou, M.; Barkun, A.; Martel, M. Effect of statin therapy on colorectal cancer. Gut., 2010, 59(11), 1572-1585.
83. Katz, M.S.; Carroll, P.R.; Cowan, J.E.; Chan, J.M.; D'Amico, A.V. Association of statin and non-steroidal anti-inflammatory drug use with prostate cancer outcomes: Results from CaPSURE. BJU. Int., 2010, 106(5), 627-632.
84. Park, H.S.; Schoenfeld, J.D.; Mailhot, R.B.; Shive, M.; Hartman, R.I.; Ogembo, R.; Mucci, L.A. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: A systematic review and meta-analysis. Ann. Oncol., 2013, 24, 1427-1434.
85. Kawata, S.; Yamasaki, E.; Nagase, T.; Inui, Y.; Ito, N.; Matsuda, Y.; Inada, M.; Tamura, S.; Noda, S.; Imai, Y.; Matsuzawa, Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer, 2001, 84(7), 886-891.
86. Glynn, S.A.; O'Sullivan, D.; Eustace, A.J.; Clynes, M.; O'Donovan, N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer, 2008, 8-9.
87. Skolarus, T.A.; Lee, E.W.; Virgo, K.S.; Katz, M.D.; Hudson, M.A.; Kibel, A.S.; Grubb, R.L. 3rd. Intravesical bacille Calmette-Guerin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J. Am. Coll. Surg., 2009, 209(2), 248-253.
88. Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson, J.R.; Kearney, P.M.; Blackwell, L.; Newman, C.; Reith, C.; Bhala, N.; Holland, L.; Peto, R.; Keech, A.; Collins, R.; Simes, J.; Baigent, C. Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS. One, 2012, 7(1), e29849.
89. Wang, C.Y.; Shui H.A.; Chang, T.C. In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int. J. Cancer, 2010, 126 (2), 578-582.